Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 182 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis

 		Rheumatoid Arthritis Phase1 China NCT07029555

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

 		Atherosclerotic Cardiovascular Disease Russian Federation NCT06858332

Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

 		Atherosclerotic Vascular Disease, Heterozygous Familial Hypercholesterolemia Spain NCT06958315

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

 		Atherosclerotic Cardiovascular Disease (ASCVD) Phase3 United States NCT06813911

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

 		Hematologic Malignancy, Solid Tumor, Advanced Malignancies Phase3 Belgium
Italy
Netherlands
United Kingdom
United States
View All
 NCT06401356

Home Reported Outcomes in C3G Study

 		C3 Glomerulopathy United States NCT07029542

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

 		Metastatic Hormone-sensitive Prostate Cancer Phase2 United States NCT06991556

Post Marketing Study on Pluvicto in Korea

 		Metastatic Castration-resistant Prostate Cancer Korea, Republic of NCT06514521

A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China

 		Paroxysmal Nocturnal Hemoglobinuria China NCT06931691

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

 		Metastatic Castration Resistant Prostate Cancer (mCRPC) Phase2 United States NCT06894511